Immunocore, one of UK biotech's brightest hopes ... and the first CAR-T therapies from Novartis and Kite Pharma, anticipated to gain approval in late 2017/ early 2018. The privately-held, Oxford ...

The healthcare industry is set for growth due to advancements in targeted treatments and personalized care and the rapid ...

Immunocore has a portfolio displaying its use in treating cancer, autoimmune diseases and other infectious diseases, and is collaborating with a number of big pharma companies. It has just ...

Immunocore has a 12 month low of $27.69 and a 12 month high of $76.98. The firm has a market capitalization of $1.60 billion, a PE ratio of -33.77 and a beta of 0.76.

GlobalData, the parent company of Pharmaceutical Technology, estimates that Kimmtrak will bring in $552m in 2029. "Immunocore and BMS partner to investigate first-line treatment for melanoma" was ...

Immunocore Holdings PLC Sponsored ADR (IMCR) closed the last trading session at $30.40, gaining 5.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term ...

Immunocore leads the way in T cell receptor-based bispecifics. By enabling a patient’s own immune system to identify and kill target cells, the bispecific molecules address major medical needs.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 6 January 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a ...

Immunocore (IMCR) Holdings set out its strategic priorities for 2025 including its plans for reaching more patients with melanoma and other diseases with high unmet needs. The Company also ...

Immunocore Holdings plc has appointed Travis Coy as Executive Vice President, Chief Financial Officer, and Head of Corporate Development effective January 1, 2025. Coy, who has over 20 years of ...

Short interest in Immunocore Holdings PLC (NASDAQ:IMCR) decreased during the last reporting period, falling from 7.06M to 6.73M. This put 15.32% of the company's publicly available shares short.